Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company's diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33 1 39 46 51 04
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees121
Next Earnings DateN/A
OptionableNot Optionable
Novacyt (LON:NCYT) Frequently Asked Questions
What is Novacyt's stock symbol?
Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."
Has Novacyt been receiving favorable news coverage?
Press coverage about NCYT stock has trended very negative on Monday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novacyt earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Novacyt.
Who are some of Novacyt's key competitors?
Some companies that are related to Novacyt include Horizon Discovery Group (HZD), Emblem (EMC), IMV (IMV), Monash IVF Group (MVF), Neptune Wellness Solutions (NEPT), Lineage Cell Therapeutics (LCTX), BioTime (BTX), Ergomed (ERGO), Bioventix (BVXP), Exicure (XCUR), Matinas BioPharma (MTNB), Exicure (XCUR), Antibe Therapeutics (ATE), Fennec Pharmaceuticals (FRX) and Helix Biopharma (HBP).
What other stocks do shareholders of Novacyt own?
Who are Novacyt's key executives?
Novacyt's management team includes the folowing people:
- Mr. Graham Mullis, CEO & Director (Age 56)
- Mr. Anthony Dyer, CFO, Company Sec. & Director
- Ms. Mandy Cowling, Corp. & Investor Relations Mang.
- Ms. Wendy Karban, Group HR Mang.
- Mr. Phillip Sefton, Managing Director of Lab21 Products Division
How do I buy shares of Novacyt?
Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Novacyt's stock price today?
One share of NCYT stock can currently be purchased for approximately GBX 145.
How big of a company is Novacyt?
What is Novacyt's official website?
How can I contact Novacyt?
The company can be reached via phone at 33 1 39 46 51 04.
MarketBeat Community Rating for Novacyt (LON NCYT)
MarketBeat's community ratings are surveys of what our community members think about Novacyt and other stocks. Vote "Outperform" if you believe NCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
